Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23885771 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL29183209 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22612643 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL21748791 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3116551 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502789 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502790 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22496874 | 0.84 | LMNA (0.37) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL2377686 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 | |
| SCHEMBL16169058 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759094-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | Takeda Pharmaceutical Company Limited (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| EP-3233827-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| WO-2008119718-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-1853586-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087543-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| US-5278165-A | Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-11 | — | — | US | disclosed |
| US-5258380-A | Antiallergens, antihistamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-11-02 | — | — | US | disclosed |
| US-5217980-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-08 | — | — | US | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |
| US-5041448-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | PIR, HAMP, AMPD2 | ALDH1A1 502/4885ACHE 1254/4885NPC1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.